Please upgrade your browser.
The following items were presented at the American Association for Cancer Research meeting in San Diego.
A biomarker that may help doctors monitor the effectiveness of common treatments for kidney cancer and non-small cell lung cancer has been identified by researchers in the Netherlands.
Bill Wondergem, 21, a Calvin biology major and biochemistry minor, has worked since his junior year as an intern in the lab of Bin Teh, a distinguished scientific investigator at the Van Andel Research Institute (VARI) and a specialist in kidney cancer.
These products have also been linked to an increased risk of kidney cancer in people who have consumed them.
Showed a 54 percent regression of the tumor volume.
Shows Tumor Regression in Patients with Advanced Renal Cancer.
Early Data on Amgens Anti-Angiogenesis Pipeline Molecules Suggest Biologic Activity Across Tumor Types
Amgen today announced results from preclinical studies suggesting a significantly greater reduction in tumor growth when AMG 386, a recombinant Fc-peptide fusion protein (peptibody) designed to bind angiopoietins 1 and 2, thereby inhibiting Tie2 dependent stimulation of endothelial cells, was combined with either of two vascular endothelial growth factor (VEGF) inhibitors -- bevacizumab or motesanib diphosphate (AMG 706) -- compared with either treatment alone (p< 0.05).
Alpha Tau Omega of the University of California Santa Barbara presents All Sorority Volleyball Tournament 2008
Volleyball tournament raises thousands for kidney cancer!!
SGN-75 is an antibody-drug conjugate (ADC) that has demonstrated potent antitumor activity at well-tolerated doses in preclinical models of renal cell cancer.
But study reveals wide variations between countries.
|NeonCRM by Neon One|